66,174 Arcutis Biotherapeutics, Inc. $ARQT Shares Sold by Privium Fund Management B.V.

Privium Fund Management B.V. trimmed its stake in Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) by 16.6% in the third quarter, HoldingsChannel.com reports. The fund owned 333,193 shares of the company’s stock after selling 66,174 shares during the quarter. Arcutis Biotherapeutics comprises approximately 1.7% of Privium Fund Management B.V.’s portfolio, making the stock its 19th biggest position. Privium Fund Management B.V.’s holdings in Arcutis Biotherapeutics were worth $8,806,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds have also made changes to their positions in the company. Oregon Public Employees Retirement Fund acquired a new stake in shares of Arcutis Biotherapeutics during the third quarter valued at $679,000. Mirae Asset Global Investments Co. Ltd. purchased a new stake in Arcutis Biotherapeutics during the 3rd quarter worth about $170,000. Profund Advisors LLC raised its stake in Arcutis Biotherapeutics by 19.3% in the 3rd quarter. Profund Advisors LLC now owns 49,700 shares of the company’s stock valued at $1,314,000 after purchasing an additional 8,045 shares during the last quarter. ProShare Advisors LLC raised its stake in Arcutis Biotherapeutics by 5.0% in the 3rd quarter. ProShare Advisors LLC now owns 20,045 shares of the company’s stock valued at $530,000 after purchasing an additional 958 shares during the last quarter. Finally, State of Wyoming raised its stake in Arcutis Biotherapeutics by 20.8% in the 3rd quarter. State of Wyoming now owns 12,182 shares of the company’s stock valued at $322,000 after purchasing an additional 2,094 shares during the last quarter.

Insider Activity

In other news, insider Todd Watanabe sold 4,377 shares of Arcutis Biotherapeutics stock in a transaction dated Monday, November 2nd. The stock was sold at an average price of $31.86, for a total transaction of $139,451.22. Following the sale, the insider directly owned 712,826 shares of the company’s stock, valued at approximately $22,710,636.36. The trade was a 0.61% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, EVP Masaru Matsuda sold 40,000 shares of the business’s stock in a transaction dated Wednesday, November 4th. The stock was sold at an average price of $34.32, for a total value of $1,372,800.00. Following the completion of the transaction, the executive vice president owned 111,289 shares in the company, valued at approximately $3,819,438.48. This trade represents a 26.44% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold a total of 123,932 shares of company stock valued at $3,553,077 in the last ninety days. 9.40% of the stock is owned by company insiders.

Arcutis Biotherapeutics News Summary

Here are the key news stories impacting Arcutis Biotherapeutics this week:

• Positive Sentiment: Arcutis raised its 2026 sales guidance, a sign of improved commercial expectations. However, investors may be weighing whether the stronger outlook is already reflected in the stock. Article: Arcutis Biotherapeutics Raised 2026 Sales Guidance
• Positive Sentiment: The company began enrolling participants in a Phase 3 study of ZORYVE cream 0.3% for moderate-to-severe atopic dermatitis. Success could expand the medicine’s potential market, though this remains a clinical-development catalyst. Article: Arcutis Begins Enrolling Phase 3 ZORYVE Study
• Neutral Sentiment: Arcutis granted stock options and restricted stock units to six new employees. The awards create some share dilution, but are routine hiring-related inducements and are not a major business update. Article: Arcutis Reports Inducement Grants
• Negative Sentiment: Third-quarter EPS was $0.06, below analyst expectations of roughly $0.17–$0.18. Revenue of $143.92 million narrowly topped forecasts, but the earnings miss appears to be the more immediate sentiment driver. Article: Arcutis Falls After Q3 Earnings Miss
• Negative Sentiment: HC Wainwright cut its EPS estimates for the first three quarters of 2027, including reducing its Q2 forecast from $0.19 to $0.14. The lowered projections add to concerns following the quarterly earnings shortfall.

Arcutis Biotherapeutics Trading Down 5.4%

NASDAQ:ARQT traded down $1.45 during mid-day trading on Friday, reaching $25.55. The company’s stock had a trading volume of 3,262,254 shares, compared to its average volume of 2,301,266. The company has a debt-to-equity ratio of 0.46, a current ratio of 2.92 and a quick ratio of 2.67. The stock has a market cap of $3.21 billion, a P/E ratio of 121.67 and a beta of 1.66. The company’s fifty day simple moving average is $27.16 and its two-hundred day simple moving average is $25.37. Arcutis Biotherapeutics, Inc. has a twelve month low of $19.30 and a twelve month high of $34.80.

Arcutis Biotherapeutics (NASDAQ:ARQT) last announced its quarterly earnings data on Wednesday, November 4th. The company reported $0.06 earnings per share for the quarter, missing the consensus estimate of $0.18 by ($0.12). Arcutis Biotherapeutics had a return on equity of 15.05% and a net margin of 6.15%. The company had revenue of $143.92 million for the quarter, compared to analysts’ expectations of $142.59 million. On average, equities analysts predict that Arcutis Biotherapeutics, Inc. will post 0.43 EPS for the current year.

Analyst Upgrades and Downgrades

A number of research analysts have issued reports on the stock. Jefferies Financial Group restated a “buy” rating and issued a $39.00 target price on shares of Arcutis Biotherapeutics in a report on Thursday, October 8th. Wall Street Zen downgraded shares of Arcutis Biotherapeutics from a “buy” rating to a “hold” rating in a report on Saturday. TD Cowen boosted their price objective on shares of Arcutis Biotherapeutics from $35.00 to $40.00 and gave the company a “buy” rating in a research report on Thursday. Cantor Fitzgerald began coverage on shares of Arcutis Biotherapeutics in a research report on Thursday, October 15th. They issued an “overweight” rating and a $48.00 price objective for the company. Finally, Weiss Ratings raised shares of Arcutis Biotherapeutics from a “hold (c-)” rating to a “hold (c)” rating in a research note on Thursday, October 29th. Eight equities research analysts have rated the stock with a Buy rating and two have given a Hold rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $39.75.

About Arcutis Biotherapeutics

Arcutis Biotherapeutics, Inc is a commercial-stage biopharmaceutical company focused on developing and delivering treatments for dermatologic conditions. The company’s portfolio is centered on therapies designed to address inflammatory skin diseases, with an emphasis on nonsteroidal topical medicines that may help patients manage chronic conditions.

Arcutis’s lead product is ZORYVE (roflumilast), a topical phosphodiesterase-4 inhibitor. ZORYVE has received U.S. Food and Drug Administration approvals for multiple dermatological uses, including plaque psoriasis, seborrheic dermatitis and atopic dermatitis, in different cream and foam formulations.